Desirox治疗铁质积聚效果如何？

It is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions.

In December 2012, Desirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy.

So, how effective is Desirox in treating iron buildup?

Therapeutic benefits of Desirox for treating iron buildup:

To analyze the effect of Desirox in the treatment of iron overload in children with β-thalassemia major.

Forty-six children with iron overload caused by β-thalassemia major who were treated from October 2015 to October 2017 were selected and divided into the Desirox group and the deferoxamine group according to the random number table method, with 23 cases in each group.

The Desirox group was treated with oral Desirox, while the deferoxamine group was treated with subcutaneous pump infusion of deferoxamine. The disease control effect after 1 year of medication, serum iron (SI), ferritin (SF), brain natriuretic peptide (BNP), troponin I (cTnI) and urinary ferritin (UF) levels before and after medication, liver and heart MRI T2 values before and after medication, and adverse drug reactions were compared between the two groups.

Results: The disease control rate in the Desirox group was 100%, which was higher than the 78.26% in the deferoxamine group (word 2=5.610, P=0.018); after treatment, the serum SI, SF, BNP and cTnI levels in the Desirox group were lower than those in the deferoxamine group, and UF levels, liver and heart MRI The T2 values were all higher than those in the deferoxamine group, and the differences were statistically significant (P<0.05); the incidence of adverse reactions in the Desirox group was lower than that in the deferoxamine group (P<0.05).

Conclusion: The treatment of iron overload in children with β-thalassemia major has better disease control effect than deferoxamine. It can effectively reduce serum SI, SF, BNP and cTnI levels, reduce the load of iron overload on the liver and heart, and the drug is safer.